Overview

A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Volunteers

Status:
Completed

Trial end date:
2010-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the pharmacokinetics of TMC278 (rilpivirine) 25 mg once daily following a preceding 2-week treatment period with efavirenz 600 mg once daily in healthy volunteers

Phase:

Phase 1

Details

Lead Sponsor:

Tibotec, Inc

Collaborator:

Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Treatments:

Efavirenz
Rilpivirine